Micron Biomedical, an Atlanta-based biotech company, secured an additional $3 million investment from J2 Ventures, bringing their Series A round total to $17 million
The company was founded in 2014 by Mark Prausnitz, Devin McAllister, and Sebastien Henry to develop dissolvable microneedle patch technology for vaccine delivery
Micron Biomedical's vaccine patch uses biocompatible polymer microneedles that dissolve after insertion, enabling painless vaccine delivery through the skin
The technology eliminates the need for refrigeration and needle disposal, reducing vaccine distribution costs and complexity
The company is developing vaccine patches for COVID-19, cancer, and other chronic diseases, with the technology currently in the development phase showing promising preclinical results
The Series A round was initiated in November 2022 and led by Global Health Investment Corporation (GHIC) and LTS Lohmann with participation from GRA Venture Fund
Dr. Matt Goldman from J2 Ventures, former Chief Medical Officer of the Defense Innovation Unit at the US Department of Defense, joined Micron's board as an observer